Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 513170, 6 pages
http://dx.doi.org/10.1155/2014/513170
Research Article

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

1Department of Hematology, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia
2Department of Pathology, School of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
3Department of Laboratory Medicine, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia
4Department of Cytology, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia
5Department of Hematology, Zagreb University Hospital Centre, Kišpatićeva 12, 10000 Zagreb, Croatia

Received 12 February 2014; Revised 20 May 2014; Accepted 23 May 2014; Published 4 June 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Toni Valković et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Palumbo and K. Anderson, “Multiple myeloma,” The New England Journal of Medicine, vol. 364, no. 11, pp. 1046–1060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Yoshiji, D. E. Gomez, M. Shibuya, and U. P. Thorgeirsson, “Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer,” Cancer Research, vol. 56, no. 9, pp. 2013–2016, 1996. View at Google Scholar · View at Scopus
  3. M. Volm, R. Koomagi, and J. Mattern, “Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer,” International Journal of Cancer, vol. 74, pp. 64–68, 1997. View at Google Scholar
  4. T. A. Olson, D. Mohanraj, L. F. Carson, and S. Ramakrishnan, “Vascular permeability factor gene expression in normal and neoplastic human ovaries,” Cancer Research, vol. 54, no. 1, pp. 276–280, 1994. View at Google Scholar · View at Scopus
  5. L. M. Ellis, Y. Takahashi, C. J. Fenoglio, K. R. Cleary, C. D. Bucana, and D. B. Evans, “Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma,” European Journal of Cancer, vol. 34, no. 3, pp. 337–340, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Valković, F. Dobrila, M. Melato, F. Sasso, C. Rizzardi, and N. Jonjić, “Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma,” Virchows Archiv, vol. 440, no. 6, pp. 583–588, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Podar, Y.-T. Tai, F. E. Davies et al., “Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration,” Blood, vol. 98, no. 2, pp. 428–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Vacca, R. Ria, D. Ribatti et al., “A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma,” Haematologica, vol. 88, no. 2, pp. 176–185, 2003. View at Google Scholar · View at Scopus
  9. F. Di Raimondo, M. P. Azzaro, G. A. Palumbo et al., “Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood,” Haematologica, vol. 85, no. 8, pp. 800–805, 2000. View at Google Scholar · View at Scopus
  10. W. T. Bellamy, L. Richter, Y. Frutiger, and T. M. Grogan, “Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies,” Cancer Research, vol. 59, no. 3, pp. 728–733, 1999. View at Google Scholar · View at Scopus
  11. B. Berse, L. F. Brown, L. Van de Water, H. F. Dvorak, and D. R. Senger, “Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,” Molecular Biology of the Cell, vol. 3, no. 2, pp. 211–220, 1992. View at Google Scholar · View at Scopus
  12. A. Franzen and D. Heinegard, “Isolation and characterization of two sialoproteins present only in bone calcified matrix,” Biochemical Journal, vol. 232, no. 3, pp. 715–724, 1985. View at Google Scholar · View at Scopus
  13. L. Liaw, M. P. Skinner, E. W. Raines et al., “The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: role of αvβ3 in smooth muscle cell migration to osteopontin in vitro,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 713–724, 1995. View at Google Scholar · View at Scopus
  14. G. F. Weber, G. F. Weber, S. Ashkar et al., “Receptor-ligand interaction between CD44 and osteopontin (Eta-1),” Science, vol. 271, no. 5248, pp. 509–512, 1996. View at Google Scholar · View at Scopus
  15. D. T. Denhardt, M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman, “Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival,” Journal of Clinical Investigation, vol. 107, no. 9, pp. 1055–1061, 2001. View at Google Scholar · View at Scopus
  16. G. F. Weber, G. S. Lett, and N. C. Haubein, “Osteopontin is a marker for cancer aggressiveness and patient survival,” British Journal of Cancer, vol. 103, no. 6, pp. 861–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Mazzali, T. Kipari, V. Ophascharoensuk, J. A. Wesson, R. Johnson, and J. Hughes, “Osteopontin—a molecule for all seasons,” QJM, vol. 95, no. 1, pp. 3–13, 2002. View at Google Scholar · View at Scopus
  18. D. F. Robbiani, K. Colon, S. Ely, S. Ely, M. Chesi, and P. L. Bergsagel, “Osteopontin dysregulation and lytic bone lesions in multiple myeloma,” Hematological Oncology, vol. 25, no. 1, pp. 16–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Colla, F. Morandi, M. Lazzaretti et al., “Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients,” Leukemia, vol. 19, no. 12, pp. 2166–2176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Sfiridaki, S. Miyakis, C. Pappa et al., “Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma,” Journal of Hematology and Oncology, vol. 4, article 22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Tanaka, M. Abe, M. Hiasa et al., “Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin,” Clinical Cancer Research, vol. 13, no. 3, pp. 816–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Dizdar, I. Barista, U. Kalyoncu et al., “Biochemical markers of bone turnover in diagnosis of myeloma bone disease,” American Journal of Hematology, vol. 82, no. 3, pp. 185–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. A. Kyle, J. A. Child, K. Anderson et al., “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group,” British Journal of Haematology, vol. 121, no. 5, pp. 749–757, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Google Scholar · View at Scopus
  25. T. Standal, H. Hjorth-Hansen, T. Rasmussen et al., “Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma,” Haematologica, vol. 89, no. 2, pp. 174–182, 2004. View at Google Scholar · View at Scopus
  26. Y. Saeki, T. Mima, T. Ishii et al., “Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications,” British Journal of Haematology, vol. 123, no. 2, pp. 263–270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Y. Kang, J. J. Lee, and W. I. Lee, “Clinical significance of serum osteopontin in patients with multiple myeloma,” The Korean Journal of Laboratory Medicine, vol. 27, no. 6, pp. 400–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Scudla, M. Budikova, P. Petrova et al., “Analysis of serum levels of selected biological parameters in monocolonal gammopathy of undetermined significance and multiple myeloma,” Klinická Onkologie, vol. 23, no. 3, pp. 171–181, 2010. View at Google Scholar
  29. V. Scudla, P. Petrova, J. Minarik, T. Pika, and J. Bacovsky, “Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma,” Neoplasma, vol. 58, no. 6, pp. 499–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Minarik, T. Pika, J. Bacovsky, P. Petrova, K. Langova, and V. Scudla, “Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance,” The Scientific World Journal, vol. 2012, Article ID 356128, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Iwasaki, T. Hamano, A. Ogata, N. Hashimoto, M. Kitano, and E. Kakishita, “Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma,” British Journal of Haematology, vol. 116, no. 4, pp. 796–802, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Sato, Y. Hattori, D. Wenlin et al., “Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity,” Japanese Journal of Cancer Research, vol. 93, no. 4, pp. 459–466, 2002. View at Google Scholar · View at Scopus
  33. E. Hatjiharissi, E. Terpos, M. Papaioannou et al., “The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma,” Hematological Oncology, vol. 22, no. 4, pp. 159–168, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Sezer, C. Jakob, J. Eucker et al., “Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma,” European Journal of Haematology, vol. 66, no. 2, pp. 83–88, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Dankbar, T. Padró, R. Leo et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma,” Blood, vol. 95, no. 8, pp. 2630–2636, 2000. View at Google Scholar · View at Scopus
  36. W. M. Swelam and D. M. Al Tamimi, “Biological impact of vascular endothelial growth factor on vessel density and survival in multiple myeloma and plasmacytoma,” Pathology Research and Practice, vol. 206, no. 11, pp. 753–759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. N. F. Andersen, T. Standal, J. L. Nielsen et al., “Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival,” British Journal of Haematology, vol. 128, no. 2, pp. 210–217, 2005. View at Publisher · View at Google Scholar · View at Scopus